{"type":"journal_article","doi":"10.1186/1742-6405-2-7","_id":"1795","publication":"AIDS Research and Therapy","publication_status":"published","issue":"1","author":[{"last_name":"Siegert","first_name":"Sandra","orcid":"0000-0001-8635-0877","id":"36ACD32E-F248-11E8-B48F-1D18A9856A87","full_name":"Sandra Siegert"},{"full_name":"Thaler, Sonja","last_name":"Thaler","first_name":"Sonja"},{"last_name":"Wagner","first_name":"Ralf","full_name":"Wagner, Ralf"},{"full_name":"Schnierle, Barbara S","first_name":"Barbara","last_name":"Schnierle"}],"status":"public","date_created":"2018-12-11T11:54:03Z","abstract":[{"text":"Background: Murine leukemia virus (MLV) vector particles can be pseudotyped with a truncated variant of the human immunodeficiency virus type 1 (HIV-1) envelope protein (Env) and selectively target gene transfer to human cells expressing both CD4 and an appropriate co-receptor. Vector transduction mimics the HIV-1 entry process and is therefore a safe tool to study HIV-1 entry. Results: Using FLY cells, which express the MLV gag and pol genes, we generated stable producer cell lines that express the HIV-1 envelope gene and a retroviral vector genome encoding the green fluorescent protein (GFP). The BH10 or 89.6 P HIV-1 Env was expressed from a bicistronic vector which allowed the rapid selection of stable cell lines. A codon-usage-optimized synthetic env gene permitted high, Rev-independent Env expression. Vectors generated by these producer cells displayed different sensitivity to entry inhibitors. Conclusion: These data illustrate that MLV/HIV-1 vectors are a valuable screening system for entry inhibitors or neutralizing antisera generated by vaccines.","lang":"eng"}],"volume":2,"publist_id":"5315","date_updated":"2021-01-12T06:53:15Z","year":"2005","month":"09","publisher":"BioMed Central","day":"12","quality_controlled":0,"title":"Assessment of HIV-1 entry inhibitors by MLV/HIV-1 pseudotyped vectors","date_published":"2005-09-12T00:00:00Z","extern":1,"citation":{"short":"S. Siegert, S. Thaler, R. Wagner, B. Schnierle, AIDS Research and Therapy 2 (2005).","mla":"Siegert, Sandra, et al. “Assessment of HIV-1 Entry Inhibitors by MLV/HIV-1 Pseudotyped Vectors.” <i>AIDS Research and Therapy</i>, vol. 2, no. 1, BioMed Central, 2005, doi:<a href=\"https://doi.org/10.1186/1742-6405-2-7\">10.1186/1742-6405-2-7</a>.","ieee":"S. Siegert, S. Thaler, R. Wagner, and B. Schnierle, “Assessment of HIV-1 entry inhibitors by MLV/HIV-1 pseudotyped vectors,” <i>AIDS Research and Therapy</i>, vol. 2, no. 1. BioMed Central, 2005.","ama":"Siegert S, Thaler S, Wagner R, Schnierle B. Assessment of HIV-1 entry inhibitors by MLV/HIV-1 pseudotyped vectors. <i>AIDS Research and Therapy</i>. 2005;2(1). doi:<a href=\"https://doi.org/10.1186/1742-6405-2-7\">10.1186/1742-6405-2-7</a>","chicago":"Siegert, Sandra, Sonja Thaler, Ralf Wagner, and Barbara Schnierle. “Assessment of HIV-1 Entry Inhibitors by MLV/HIV-1 Pseudotyped Vectors.” <i>AIDS Research and Therapy</i>. BioMed Central, 2005. <a href=\"https://doi.org/10.1186/1742-6405-2-7\">https://doi.org/10.1186/1742-6405-2-7</a>.","ista":"Siegert S, Thaler S, Wagner R, Schnierle B. 2005. Assessment of HIV-1 entry inhibitors by MLV/HIV-1 pseudotyped vectors. AIDS Research and Therapy. 2(1).","apa":"Siegert, S., Thaler, S., Wagner, R., &#38; Schnierle, B. (2005). Assessment of HIV-1 entry inhibitors by MLV/HIV-1 pseudotyped vectors. <i>AIDS Research and Therapy</i>. BioMed Central. <a href=\"https://doi.org/10.1186/1742-6405-2-7\">https://doi.org/10.1186/1742-6405-2-7</a>"},"intvolume":"         2"}